Abstract
The Fifth International Pharmaco-Economic Conference on Alzheimer’s Disease was held in New York, on March 27–29 in 2008. The attendees included researchers and key opinion leaders within the academia, pharmaceutical industry, patient organizations and regulatory bodies, collecting the worldwide leading expertise in Alzheimer research today. A summary of the presentations and conclusions from the discussions are presented in this publication. Pharmaco-economics need to play a leading role in develo** and communicating evidence of the value of anti-dementia drugs, now and in the future. For the development of evidence, the challenges include transparency and standardization of costs of care assessment, improved diagnostics for identifying target patient groups, improved endpoints for assessing outcomes and improved models for assessing the long term consequences of competing treatment strategies. For the communication of evidence, the challenge lies in convincing decision makers to recognize the integrated burden of the disease, including its interaction with comorbidities and burden on caregivers, and to consider the consequences of competing treatment strategies from a societal perspective.
Similar content being viewed by others
References
Wimo, A., B. Winblad, and L. Jonsson, An estimate of the total worldwide societal costs of dementia in 2005. Alzheimer’s and Dementia, 2007. 3(2): p. 81–91.
Wimo, A., L. Jönsson, and B. Winblad., The worldwide prevalence and direct costs of dementia in 2003. Dementia and Geriatric Cognitive Disorders, in press., 2006.
Ferri, C. P., et al., Global prevalence of dementia: a Delphi consensus study. Lancet, 2005. 366(9503): p. 2112–2117.
Dementia in Europe Yearbook 2006, Alzheimer Europe.
Wimo, A. and B. Winblad, Resource Utilization in dementia: RUD Lite. Brain & Aging, 2003. 3: p. p. 48–59.
Wimo, A. and G. Nordberg, Validity and reliability of assessments of time Comparisons of direct observations and estimates of time by the use of the resource utilization in dementia (RUD)-instrument. Arch Gerontol Geriatr, 2006.
Courtney, C., et al., Long-term donepezil treatment in 565 patients with Alzheimer’s disease (AD2000): randomised double-blind trial. Lancet, 2004. 363(9427): p. 2105–2115.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Gustavsson, A., Jonsson, L., Fillit, H. et al. IPECAD5 — Fifth International Pharmaco-Economic Conference on Alzheimer’s Disease. J Nutr Health Aging 14, 358–360 (2010). https://doi.org/10.1007/s12603-010-0080-3
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12603-010-0080-3